Loading...
At this year's Gastrointestinal Cancers Symposium, held January 17–19 in San Francisco, investigators discussed the latest findings in gastrointestinal (GI) cancer research. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, was on hand to review the following key presentations on new GI cancer treatments. All abstracts can be viewed in the symposium's meeting library.
Kojima and colleagues reported results of a randomized, open-label, phase III trial (KEYNOTE-181) comparing treatment with pembrolizumab to investigators' choice of paclitaxel, docetaxel, or irinotecan in 618 patients with squamous cancer or adenocarcinoma of the eso…